Navigation Links
The long-term fiscal impact of funding cuts for IVF in Denmark

In 2009, 1,547 ART children were born in public clinics in Denmark, projecting a net tax revenue of 224 million and 247 million in 25 and 50 years respectively. The authors of the study calculated that reductions of 30-50% in ART cycles following the new policy would lead to cost savings of 67 - 111 million for the Danish government in 2034. By 2059 however, when the IVF cohort are 50 years of age, the government would have lost 74 - 123 million due to less tax contributions from fewer children born.

"The most common argument governments use not to fund ART is that fertility treatments are too expensive," said Mark Connolly, lead author of the study, University of Groningen. "Infertility is perceived to be a low priority illness that focuses on unmet needs of present day society. However, when the broader consequences of fertility funding are considered, many of today's fiscal problems such as the ageing population, low birth rates and the declining number of working adults are all partly mitigated by ART conceived children, which in some countries represent 4-5% of the future work force."

An investment of 11,097 for an ART conceived singleton born to a woman younger than 40 is valued at 155,700 and 154,360 in cumulative discounted net tax revenue, when the child is 25 and 50 respectively. For a woman aged over 40, where the cost per birth is 26,147, the investment is valued at 170,470 and 139,600.

"Although investments in reproductive medicine take many years for governments to benefit, the net tax receipts are comparable with naturally conceived children," said Sren Ziebe, co-author of this study, Rigshospital at Copenhagen University. "Both ART conceived and naturally conceived children show a negative balance for the Danish government at age 25. However, at 50 years of age, after 30 years of tax contributions, the net tax benefit of both types of children is considerably high for the state."

The scientists used a modified generational accounting framework to estimate the return on investment for the Danish government based on public funding of IVF and ICSI (intracytoplasmic sperm injection). In the model, publicly funded IVF-treatment costs were added to the sum of discounted age-specific transfers between the government and the individual (tax contributions, healthcare, social benefits, education and retirement contributions) to calculate the net present value of investment in ART. This was compared to naturally conceived children, using the same calculation without ART cost depreciation. This analysis is based on annualised net tax receipts attributed to a single year of ART children and would be equally applicable in subsequent years, therefore compounding the fiscal effects of the policy change over time.

The average cost per live birth was estimated as 2,675 per cycle [1]. The model assumed a 30-50% reduction in ART births following the implementation of the new policy. The authors believe this to be an underestimate since only IVF/ICSI births in public clinics were considered. This estimated reduction is comparable to Germany, when the government introduced co-payments for ART of 50% in 2004. This resulted in an estimated 10,000 fewer births in one year, a small but meaningful demographic impact.


Contact: Hanna Hanssen
European Society of Human Reproduction and Embryology

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. Birth control has long-term effect on hormone exposure
3. Exposing chicks to maternal stress leads to long-term reproductive success
4. European biodiversity and ecosystem scientists merge and gear up for long-term research
5. Long-term use of diabetes drugs by women significantly increases risk of fractures
6. Vitamin D deficiency in infants and nursing mothers carries long-term disease risks
7. Long-term recovery of reefs from bleaching requires local action to increase resilience
8. Long-term study of orchard ground cover management systems
9. Alzheimers disease therapeutic prevents long-term damage from TBI in pre-clinical studies
10. Study finds multidrug-resistant gram-negative bacteria high in long-term care
11. Neuroscientists discover long-term potentiation in the olfactory bulb
Post Your Comments:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
Breaking Biology Technology: